uniQure N.V. (NASDAQ:QURE)
| Market Cap | 1.45B-66.6% |
| Revenue (ttm) | 18.67M+30.2% |
| Net Income | -252.21M-26.7% |
| EPS | -4.04-3.1% |
| Shares Out | 69.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,323,243 |
| Open | 21.18 |
| Previous Close | 21.28 |
| Day's Range | 20.33 - 21.75 |
| 52-Week Range | 8.73 - 71.50 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 52.18(+148.83%) |
| Earnings Date | Nov 9, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$QURE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in QURE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QURE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QURE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
QURE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Fair value loss - Liability related to pre-funded warrants | $12.20M | 67.32% |
| Segment reporting | $5.84M | 32.23% |
| Fair value (loss) / gain - contingent consideration | $82.00K | 0.45% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New QURE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QURE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in QURE
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $46.27M |
| VXFVanguard Extended Market ETF | $38.47M |
| IBBiShares Biotechnology ETF | $10.47M |
| SCHASchwab U.S. Small-Cap ETF | $7.66M |
| VHTVanguard Health Care ETF | $7.66M |
| PTHInvesco Dorsey Wright Healthcare Momentum ETF | $2.82M |
Estimated from each fund’s disclosed top holdings × AUM
QURE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from QURE’s recent data — informational, not investment advice